Archived Press Releases
06.22.10 sanofi-aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics
05.27.10 Regulus Therapeutics Receives Exclusive License for Intellectual Property to microRNA-21 for Diseases of the Heart, Liver, and Kidney
04.15.10 Regulus Therapeutics Presents New Pre-clinical Data on microRNA Therapeutics for Diabetes
03.29.10 Regulus Therapeutics and Collaborators Publish Pre-clinical In Vivo Efficacy Data on microRNA Therapeutics targeting microRNA-10b in Models of Breast Cancer Metastasis
03.17.10 Regulus Announces U.S. Allowance of Stanford Patent Application Covering miR-181a Function in Immune Cells
02.25.10 Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122
01.25.10 Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21
01.15.10 Regulus Therapeutics Present New Pre-clinical Data from Multiple Therapeutic Programs at Keystone Symposium
01.11.10 Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
